var data={"title":"Lenalidomide: Drug information","body":"<div id=\"topicContent\" class=\"utdArticleSection utdStyle\"><div id=\"drugTitle\">Lenalidomide: Drug information</div><div id=\"lexiTitleImg\"></div><div class=\"clear\"></div><div id=\"lcoSearchClickUrl\"><a href=\"http://online.lexi.com/lco/action/api/find/globalid/190661?utd=1\" target=\"_blank\">Access Lexicomp Online here.</a></div><div id=\"drugCopy\">Copyright 1978-2018 Lexicomp, Inc. All rights reserved.</div><div id=\"topicText\">(For additional information <a href=\"topic.htm?path=lenalidomide-patient-drug-information\" class=\"drug drug_patient\">see &quot;Lenalidomide: Patient drug information&quot;</a>)<br></br>For abbreviations and symbols that may be used in Lexicomp (<a href=\"image.htm?imageKey=DRUG%2F57469\" class=\"graphic graphic_table\">show table</a>)<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F5709009\" class=\"block black-box-warn drugH1Div\"><span class=\"drugH1\">ALERT: US Boxed Warning</span>\n    <div class=\"collapsible\">\n      <span class=\"collapsible-title\">Fetal risk:</span>\n      <div class=\"collapsible-wrap\">\n        <p style=\"text-indent:-2em;margin-left:2em;\">Do not use lenalidomide during pregnancy. Lenalidomide, a thalidomide analogue, caused limb abnormalities in a developmental monkey study. Thalidomide is a known human teratogen that causes severe, life-threatening human birth defects. If lenalidomide is used during pregnancy, it may cause birth defects or embryo-fetal death. In women of reproductive potential, obtain 2 negative pregnancy tests before starting lenalidomide treatment. Women of childbearing potential must use 2 forms of contraception or continuously abstain from heterosexual sex during and for 4 weeks after lenalidomide treatment. To avoid embryo-fetal exposure to lenalidomide, it is only available under a restricted distribution program called Revlimid REMS.</p>\n        <p style=\"text-indent:-2em;margin-left:2em;\">Information about the Revlimid REMS program is available at http://www.celgeneriskmanagement.com or by calling the manufacturer's toll-free number 1-888-423-5436.</p></div>\r\n</div>\r\n\n    <div class=\"collapsible\">\n      <span class=\"collapsible-title\">Hematologic toxicity:</span>\n      <div class=\"collapsible-wrap\">\n        <p style=\"text-indent:-2em;margin-left:2em;\">Lenalidomide can cause significant neutropenia and thrombocytopenia. Eighty percent of patients with deletion 5q myelodysplastic syndromes had to have a dose delay/reduction during the major study. Thirty-four percent of patients had to have a second dose delay/reduction. Grade 3 or 4 hematologic toxicity was seen in 80% of patients enrolled in the study. Patients on therapy for deletion 5q myelodysplastic syndromes should have their complete blood cell count (CBC) monitored weekly for the first 8 weeks of therapy and at least monthly thereafter. Patients may require dose interruption and/or reduction. Patients may require use of blood product support and/or growth factors.</p></div>\r\n</div>\r\n\n    <div class=\"collapsible\">\n      <span class=\"collapsible-title\">Venous and arterial thromboembolism:</span>\n      <div class=\"collapsible-wrap\">\n        <p style=\"text-indent:-2em;margin-left:2em;\">Lenalidomide has demonstrated a significantly increased risk of deep vein thrombosis (DVT) and pulmonary embolism (PE), as well as risk of myocardial infarction and stroke in patients with multiple myeloma who were treated with lenalidomide and dexamethasone therapy. Monitor for and advise patients about the signs and symptoms of thromboembolism. Advise patients to seek immediate medical care if they develop symptoms such as shortness of breath, chest pain, or arm or leg swelling. Thromboprophylaxis is recommended and the choice of regimen should be based on an assessment of the patient's underlying risk factors.</p></div>\r\n</div>\r\n</div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F2407571\" class=\"list ubnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: US</span>\n    <ul>\n      <li>Revlimid</li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F6027963\" class=\"list cbnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: Canada</span>\n    <ul>\n      <li>Revlimid</li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F2407576\" class=\"ex_sect_xr thclist drugH1Div drugBrandNames\"><span class=\"drugH1\">Pharmacologic Category</span>\n    <ul>\n      <li>\n        Angiogenesis Inhibitor;</li>\n      <li>\n        Antineoplastic Agent;</li>\n      <li>\n        Immunomodulator, Systemic</li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F2407611\" class=\"block doa drugH1Div\"><span class=\"drugH1\">Dosing: Adult</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Mantle cell lymphoma (MCL):</b> Oral: 25 mg once daily for 21 days of a 28-day treatment cycle; continue until disease progression or unacceptable toxicity (Goy 2013)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Multiple myeloma:</b> Oral: 25 mg once daily for 21 days of a 28-day treatment cycle (in combination with dexamethasone). In patients not eligible for autologous stem cell transplantation, continue until disease progression or unacceptable toxicity; in transplant eligible patients, hematopoietic stem cell mobilization should occur within 4 cycles of a lenalidomide-containing therapy.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Multiple myeloma, maintenance (following autologous stem cell transplant)</b>: Oral: 10 mg once daily (begin after adequate hematologic recovery); continue until disease progression or unacceptable toxicity. If tolerated, may increase dose to 15 mg once daily after 3 cycles (each cycle is 28 days).</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <i>Off-label dosing</i>: 10 mg once daily for 21 days of a 28-day treatment cycle until relapse (Palumbo 2010)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Myelodysplastic syndrome (MDS) with deletion 5q:</b> Oral: 10 mg once daily</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Chronic lymphocytic leukemia (CLL), relapsed/refractory (off-label use):</b> Oral: 10 mg once daily beginning on day 9 of cycle 1; administer continuously in combination with cyclic rituximab (Badoux 2013)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Diffuse large B-cell lymphoma, relapsed/refractory (off-label use):</b> Oral: 25 mg once daily for 21 days of a 28-day treatment cycle for up to 1 year (Wiernik 2008)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Multiple myeloma, newly diagnosed (off-label combination):</b> Oral: 25 mg once daily for 14 days of a 21-day cycle (in combination with bortezomib and dexamethasone) for 8 cycles (Kumar 2012; Richardson 2010) <b>or</b> 25 mg once daily for 21 days of a 28-day cycle (in combination with carfilzomib and dexamethasone) for up to 8 cycles (Jakubowiak 2012)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Multiple myeloma, relapsed (off-label combinations):</b> Adults: Oral: 25 mg once daily for 21 days of 28-day cycle (in combination with carfilzomib and dexamethasone) until disease progression or unacceptable toxicity (Stewart 2015) <b>or</b> 25 mg once daily for 21 days of a 28-day cycle (in combination with daratumumab and dexamethasone) until disease progression or unacceptable toxicity; refer to the IMWG recommendations for Dosing in Renal Impairment (Dimopoulos 2016a; Dimopoulos 2016b).</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Myelodysplastic syndrome (MDS), lower risk, without deletion 5q (off-label use):</b> Oral: 10 mg once daily (Raza 2008)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Systemic light chain amyloidosis (off-label use):</b> Oral: 15 mg once daily for 21 days of a 28-day cycle (in combination with dexamethasone) (Nair 2012; Sanchorawala 2007)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F2407612\" class=\"block doe drugH1Div\"><span class=\"drugH1\">Dosing: Geriatric</span>\n    <p style=\"text-indent:0em;display:inline\">Refer to adult dosing. Due to the potential for decreased renal function in the elderly, select dose carefully and closely monitor renal function.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F2407613\" class=\"block dor drugH1Div\"><span class=\"drugH1\">Dosing: Renal Impairment</span>\n    <p style=\"text-indent:0em;display:inline\">\n      <b>Note:</b> <i><b>Maintain appropriate number of treatment days per cycle based on indication and/or protocol.</b></i> Further individualize (increase or decrease dose) based on tolerance.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <i>Recommended initial dose adjustment in the manufacturer's labeling:</i></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">MCL and multiple myeloma (combination therapy with dexamethasone):</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">CrCl &gt;60 mL/minute: No dosage adjustment necessary.</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">CrCl 30 to 60 mL/minute: 10 mg once daily (for multiple myeloma, may increase to 15 mg once daily after 2 cycles if nonresponsive but tolerating treatment)</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">CrCl &lt;30 mL/minute (nondialysis dependent): 15 mg every 48 hours</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">ESRD: CrCl &lt;30 mL/minute and dialysis dependent: 5 mg once daily (administer after dialysis on dialysis days)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">MDS and multiple myeloma (maintenance treatment after autologous stem cell transplant):</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">CrCl &gt;60 mL/minute: No dosage adjustment necessary.</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">CrCl 30 to 60 mL/minute: 5 mg once daily</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">CrCl &lt;30 mL/minute (nondialysis dependent): 2.5 mg once daily</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">ESRD: CrCl &lt;30 mL/minute and dialysis dependent: 2.5 mg once daily (administer after dialysis on dialysis days)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Dialysis removal: Approximately 30% removed during a 4-hour hemodialysis session</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <i>The International Myeloma Working Group (IMWG) recommendations (Dimopoulos 2016b):</i></p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">The IMWG recommends use of the Chronic Kidney Disease Epidemiology Collaboration (CKD-EPI) equation (preferred) or the Modification of Diet in Renal Disease (MDRD) formula to evaluate renal function estimation in multiple myeloma patients with a stable serum creatinine.</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">\n      <i>Combination therapy with dexamethasone: </i></p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">CrCl &ge;60 mL/minute: 25 mg once daily (no dosage adjustment necessary).</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">CrCl 30 to 59 mL/minute: 10 mg once daily (may increase to 15 mg once daily in the absence of toxicity).</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">CrCl 15 to 29 mL/minute: 15 mg once every other day; may adjust to 10 mg once daily.</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">CrCl &lt;15 mL/minute: 5 mg once daily.</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">ESRD on dialysis: 5 mg once daily.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F16160282\" class=\"block doh drugH1Div\"><span class=\"drugH1\">Dosing: Hepatic Impairment</span>\n    <p style=\"text-indent:0em;display:inline\">There are no dosage adjustments provided in the manufacturer's labeling (has not been studied). However, lenalidomide undergoes minimal hepatic metabolism.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F2407614\" class=\"block dot drugH1Div\"><span class=\"drugH1\">Dosing: Adjustment for Toxicity</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>NONHEMATOLOGIC toxicities:</b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <i>Dermatologic toxicities:</i></p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Skin rash, grade 2 or 3: Consider interrupting or discontinuing treatment.</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Angioedema, grade 4 rash, exfoliative or bullous rash, or suspected Stevens-Johnson syndrome, toxic epidermal necrolysis, or drug reaction with eosinophilia and systemic symptoms (DRESS): Discontinue treatment; do not rechallenge.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <i>Tumor flare reaction:</i></p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Grade 1 or 2: Continue therapy at physician's discretion; may consider symptom management with corticosteroids, nonsteroidal anti-inflammatory drugs (NSAIDs) and/or analgesic therapy.</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Grade 3 or 4: Interrupt therapy until resolved to &le; grade 1; consider symptom management with corticosteroids, nonsteroidal anti-inflammatory drugs (NSAIDs) and/or analgesic therapy.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <i>Other toxicities:</i> For additional treatment-related grade 3/4 toxicities, hold treatment and restart (if appropriate) at next lower dose level when toxicity has resolved to &le; grade 2.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;margin-top:2em;\">\n      <b>HEMATOLOGIC toxicities:</b></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Adjustment for thrombocytopenia in MCL:</b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Platelets &lt;50,000/mm<sup>3</sup>: Hold treatment, check CBC weekly</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">When platelets return to &ge;50,000/mm<sup>3</sup>: Resume treatment at 5 mg below previous dose; do not dose below 5 mg daily</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Adjustment for neutropenia in MCL: </b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">ANC &lt;1,000/mm<sup>3</sup> for at least 7 days or associated with fever (&ge;38.5&deg;C [101&deg;F]): Hold treatment, check CBC weekly</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">ANC &lt;500/mm<sup>3</sup>: Hold treatment, check CBC weekly</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">When ANC returns to &ge;1,000/mm<sup>3</sup>: Resume treatment at 5 mg below previous dose; do not dose below 5 mg daily</p>\n    <p style=\"text-indent:-2em;margin-left:2em;margin-top:2em;\">\n      <b>Adjustment for thrombocytopenia in MDS:</b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <i>Thrombocytopenia developing <b>within</b> 4 weeks of beginning treatment at 10 mg daily:</i></p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Baseline platelets &ge;100,000/mm<sup>3</sup>:</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">If platelets &lt;50,000/mm<sup>3</sup>: Hold treatment</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">When platelets return to &ge;50,000/mm<sup>3</sup>: Resume treatment at 5 mg daily</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Baseline platelets &lt;100,000/mm<sup>3</sup>:</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">If platelets fall to 50% of baseline: Hold treatment</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">If baseline &ge;60,000/mm<sup>3</sup> and platelet level returns to &ge;50,000/mm<sup>3</sup>: Resume at 5 mg daily</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">If baseline &lt;60,000/mm<sup>3</sup> and platelet level returns to &ge;30,000/mm<sup>3</sup>: Resume at 5 mg daily</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <i>Thrombocytopenia developing <b>after</b> 4 weeks of beginning treatment at 10 mg daily:</i></p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Platelets &lt;30,000/mm<sup>3</sup> <b>or</b> &lt;50,000/mm<sup>3</sup> with platelet transfusions: Hold treatment</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">When platelets return to &ge;30,000/mm<sup>3</sup> (without hemostatic failure): Resume at 5 mg daily</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <i>Thrombocytopenia developing during treatment at 5 mg daily:</i></p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Platelets &lt;30,000/mm<sup>3</sup> <b>or</b> &lt;50,000/mm<sup>3</sup> with platelet transfusions: Hold treatment</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">When platelets return to &ge;30,000/mm<sup>3</sup> (without hemostatic failure): Resume at 2.5 mg once daily</p>\n    <p style=\"text-indent:-2em;margin-left:2em;margin-top:2em;\">\n      <b>Adjustment for neutropenia in MDS:</b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <i>Neutropenia developing <b>within</b> 4 weeks of beginning treatment at 10 mg daily:</i></p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">For baseline absolute neutrophil count (ANC) &ge;1,000/mm<sup>3</sup>:</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">ANC &lt;750/mm<sup>3</sup>: Hold treatment</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">When ANC returns to &ge;1,000/mm<sup>3</sup>: Resume at 5 mg daily</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">For baseline absolute neutrophil count (ANC) &lt;1,000/mm<sup>3</sup>:</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">ANC &lt;500/mm<sup>3</sup>: Hold treatment</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">When ANC returns to &ge;500/mm<sup>3</sup>: Resume at 5 mg daily</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <i>Neutropenia developing <b>after</b> 4 weeks of beginning treatment at 10 mg daily:</i></p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">ANC &lt;500/mm<sup>3</sup> for &ge;7 days or associated with fever (&ge;38.5&deg;C [101&deg;F]): Hold treatment</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">When ANC returns to &ge;500/mm<sup>3</sup>: Resume at 5 mg daily</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <i>Neutropenia developing during treatment at 5 mg daily:</i></p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">ANC &lt;500/mm<sup>3</sup> for &ge;7 days or associated with fever (&ge;38.5&deg;C [101&deg;F]): Hold treatment</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">When ANC returns to &ge;500/mm<sup>3</sup>: Resume at 2.5 mg once daily</p>\n    <p style=\"text-indent:-2em;margin-left:2em;margin-top:2em;\">\n      <b>Adjustment for thrombocytopenia in multiple myeloma:</b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <i>Combination therapy with dexamethasone:</i></p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Platelets &lt;30,000/mm<sup>3</sup>: Hold treatment, check CBC weekly</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">When platelets return to &ge;30,000/mm<sup>3</sup>: Resume at next lower dose; do not dose below 2.5 mg daily</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Additional occurrence of platelets &lt;30,000/mm<sup>3</sup>: Hold treatment</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">When platelets return to &ge;30,000/mm<sup>3</sup>: Resume treatment at next lower dose; do not dose below 2.5 mg daily</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <i>Maintenance following autologous stem cell transplant:</i></p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Platelets &lt;30,000/mm<sup>3</sup>: Hold treatment, check CBC weekly</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">When platelets return to &ge;30,000/mm<sup>3</sup>: Resume at next lower dose; maintain continuous daily dosing</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Additional occurrence of platelets &lt;30,000/mm<sup>3</sup> (and current dose is 5 mg once daily): Hold treatment</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">When platelets return to &ge;30,000/mm<sup>3</sup> (and current dose is 5 mg once daily): Resume treatment at 5 mg daily on days 1 to 21 of a 28-day cycle; do not dose below 5 mg daily on days 1 to 21 of a 28-day cycle.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;margin-top:2em;\">\n      <b>Adjustment for neutropenia in multiple myeloma:</b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <i>Combination therapy with dexamethasone:</i></p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">ANC &lt;1,000/mm<sup>3</sup>: Hold treatment, check CBC weekly</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">When ANC returns to &ge;1,000/mm<sup>3</sup> (with neutropenia as only toxicity): Resume at 25 mg daily or initial starting dose</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">When ANC returns to &ge;1,000/mm<sup>3</sup> (with additional toxicities): Resume at next lower dose; do not dose below 2.5 mg daily</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Additional occurrence of ANC &lt;1,000/mm<sup>3</sup>: Hold treatment</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">When ANC returns to &ge;1,000/mm<sup>3</sup>: Resume treatment at next lower dose; do not dose below 2.5 mg daily</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <i>Maintenance following autologous stem cell transplant:</i></p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">ANC &lt;500/mm<sup>3</sup>: Hold treatment, check CBC weekly</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">When ANC returns to &ge;500/mm<sup>3</sup>: Resume at next lower dose; maintain continuous daily dosing</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Additional occurrence of ANC &lt;500/mm<sup>3</sup> (and current dose is 5 mg daily): Hold treatment</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">When ANC returns to &ge;500/mm<sup>3</sup>: Resume treatment at 5 mg daily on days 1 to 21 of a 28-day cycle; do not dose below 5 mg daily on days 1 to 21 of a 28-day cycle.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F2407623\" class=\"block foc drugH1Div\"><span class=\"drugH1\">Dosage Forms</span>\n    <p style=\"text-indent:0em;text-align:justify;display:inline\">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Capsule, Oral: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Revlimid: 2.5 mg [contains fd&amp;c blue #2 (indigotine)]</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Revlimid: 5 mg</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Revlimid: 10 mg, 15 mg, 20 mg [contains fd&amp;c blue #2 (indigotine)]</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Revlimid: 25 mg</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F2407574\" class=\"block geq drugH1Div\"><span class=\"drugH1\">Generic Equivalent Available (US)</span>\n    <p style=\"text-indent:0em;display:inline\">No</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F11234038\" class=\"block accres drugH1Div\"><span class=\"drugH1\">Prescribing and Access Restrictions</span>\n    <p style=\"text-indent:0em;display:inline\">In Canada, distribution is restricted through RevAid (www.RevAid.ca or 1-888-738-2431).</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F7874837\" class=\"block meg drugH1Div\"><span class=\"drugH1\">Medication Guide and/or Vaccine Information Statement (VIS)</span>\n    <p style=\"text-indent:0em;display:inline\">An FDA-approved patient medication guide, which is available with the product information and at <a target=\"_blank\" href=\"http://www.fda.gov/downloads/Drugs/DrugSafety/ucm111335.pdf&amp;token=SHauxSdf9qNc6lLK16E8IL3aNdSXbSTKjKzr5jWxn/9UPgXiAK20QB1EgZj8b1kxQlH+0C9wzbyz4vD74jG4iw==&amp;TOPIC_ID=9822\" target=\"_blank\">http://www.fda.gov/downloads/Drugs/DrugSafety/ucm111335.pdf</a>, must be dispensed with this medication.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F2407615\" class=\"block adm drugH1Div\"><span class=\"drugH1\">Administration</span>\n    <p style=\"text-indent:0em;display:inline\">Administer at about the same time each day with water; administer with or without food. Swallow capsule whole; do not break, open, or chew.</p>\n    <p style=\"text-indent:0em;margin-top:2em;\">\n      <i>Missed doses:</i> May administer a missed dose if within 12 hours of usual dosing time. If greater than 12 hours, patient should skip dose for that day and resume usual dosing the following day. Patient should <b>not</b> take 2 doses to make up for a missed dose.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F49104526\" class=\"block hazard drugH1Div\"><span class=\"drugH1\">Hazardous Drugs Handling Considerations</span>\n    <p style=\"text-indent:0em;\">Hazardous agent (NIOSH 2016 [group 2]).</p>\n    <p style=\"text-indent:0em;margin-top:2em;\">Use appropriate precautions for receiving, handling, administration, and disposal. Gloves (single) should be worn during receiving, unpacking, and placing in storage. NIOSH recommends single gloving for administration of intact tablets or capsules (NIOSH 2016). Assess risk to determine appropriate containment strategy (USP-NF 2017).</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F2407578\" class=\"block use drugH1Div\"><span class=\"drugH1\">Use</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Mantle cell lymphoma:</b> Treatment of patients with mantle cell lymphoma that has relapsed or progressed after 2 prior therapies (one of which included bortezomib).</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Multiple myeloma:</b> Treatment of multiple myeloma (in combination with dexamethasone) and as maintenance therapy following autologous hematopoietic stem cell transplantation.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Myelodysplastic syndromes:</b> Treatment of patients with transfusion-dependent anemia due to low- or intermediate-1-risk myelodysplastic syndromes (MDS) associated with a deletion 5q (del 5q) cytogenetic abnormality with or without additional cytogenetic abnormalities</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Limitations of use: Lenalidomide is not indicated and is not recommended for the treatment of chronic lymphocytic leukemia (CLL) outside of controlled clinical trials.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F25473682\" class=\"block off-label drugH1Div\"><span class=\"drugH1\">Use: Off-Label</span>\n    <p>Chronic lymphocytic leukemia, relapsed or refractory; Diffuse large B-cell lymphoma, relapsed or refractory; Myelodysplastic syndrome (MDS) without deletion 5q; Multiple myeloma, newly diagnosed; Systemic light chain amyloidosis</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F3401642\" class=\"block mst drugH1Div\"><span class=\"drugH1\">Medication Safety Issues</span>\n    <div class=\"collapsible\">\n      <span class=\"collapsible-title\">Sound-alike/look-alike issues:</span>\n      <div class=\"collapsible-wrap\">\n        <p style=\"text-indent:-2em;margin-left:4em;\">Lenalidomide may be confused with leflunomide, pomalidomide, thalidomide</p>\n        <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Revlimid may be confused with Thalomid</p></div>\r\n</div>\r\n\n    <div class=\"collapsible\">\n      <span class=\"collapsible-title\">High alert medication:</span>\n      <div class=\"collapsible-wrap\">\n        <p style=\"text-indent:-2em;margin-left:4em;\">This medication is in a class the Institute for Safe Medication Practices (ISMP) includes among its list of drug classes which have a heightened risk of causing significant patient harm when used in error.</p></div>\r\n</div>\r\n\n    <div class=\"collapsible\">\n      <span class=\"collapsible-title\">International issues:</span>\n      <div class=\"collapsible-wrap\">\n        <p style=\"text-indent:-2em;margin-left:4em;\">Revlimid may be confused with Revolade, a brand name for eltrombopag [Canada]. </p></div>\r\n</div>\r\n</div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F2407590\" class=\"block adr drugH1Div\"><span class=\"drugH1\">Adverse Reactions</span>\n    <p style=\"text-indent:0em;display:inline\">May vary based on indication.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">&gt;10%:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Cardiovascular: Peripheral edema (16% to 20%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Central nervous system: Fatigue (11% to 34%), dizziness (20%), headache (9% to 20%), paresthesia (13%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Dermatologic: Pruritus (MDS: 42%; MCL: 17%), skin rash (8% to 36%), xeroderma (&le;11%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Endocrine &amp; metabolic: Weight loss (13%), hypokalemia (7% to 13%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Gastrointestinal: Diarrhea (MM maintenance, MDS: 39% to 49%; MCL: 31%), nausea (11% to 30%), constipation (13% to 24%), gastroenteritis (23%), decreased appetite (14%), abdominal pain (10% to 12%), vomiting (6% to 12%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Genitourinary: Urinary tract infection (4% to 11%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Hematologic &amp; oncologic: Thrombocytopenia (24% to 62%; grades 3/4: 13% to 50%), neutropenia (49% to 61%; grades 3/4: 43% to 54%), leukopenia (8% to 32%; grades 3/4: 5% to 24%), anemia (MCL: 31%, grades 3/4: 11%, MDS, MM maintenance: 9% to 12%, grades 3/4: 4% to 6%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Infection: Influenza (13%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Neuromuscular &amp; skeletal: Muscle spasm (MM maintenance: 33%; MCL: 13%), weakness (14% to 30%), arthralgia (MDS: 22%; MCL: 8%), back pain (13% to 21%), muscle cramps (18%), limb pain (11%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Respiratory: Bronchitis (MM: 44%; MDS: 6%), nasopharyngitis (&le;35%), cough (20% to 28%), pneumonia (12% to 17%), dyspnea (6% to 17%; includes exacerbation), pharyngitis (16%), epistaxis (15%), upper respiratory tract infection (11% to 15%), rhinitis (7% to 15%), sinusitis (&le;14%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Miscellaneous: Fever (21% to 23%; may be intermittent)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">1% to 10%:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Cardiovascular: Edema (10%), hypotension (7%), hypertension (6%), chest pain (5%), palpitations (5%), deep vein thrombosis (2% to 4%), pulmonary embolism (1% to 2%), cardiac failure</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Central nervous system: Insomnia (10%), peripheral neuropathy (5% to 10%), hypoesthesia (7%), pain (7%), rigors (6%), chills, lethargy, vertigo</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Dermatologic: Night sweats (8%), diaphoresis (7%), ecchymoses (5%), erythema (5%), cellulitis (2% to 5%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Endocrine &amp; metabolic: Dehydration (7%), hypothyroidism (7%), hypomagnesemia (6%), hypocalcemia (3%), hyponatremia (2%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Gastrointestinal: Anorexia (10%), upper abdominal pain (7% to 8%), xerostomia (7%), dysgeusia (6%), loose stools (6%), oral herpes</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Genitourinary: Dysuria (7%), urolithiasis (ureter)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Hematologic &amp; oncologic: Tumor flare (10%), bruise (8%), lymphocytopenia (4% to 7%; grades 3/4: 4%), febrile neutropenia (2% to 6%; grades 3/4: 2% to 6%), pancytopenia (4%; grades 3/4: 2%), squamous cell carcinoma of skin (3%), granulocytopenia (grades 3/4: 2%), myelodysplastic syndrome (&le;1%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Hepatic: Increased serum ALT (8%), hyperbilirubinemia (1%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Hypersensitivity: Hypersensitivity reaction</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Infection: Herpes zoster (10%), infection (6%), sepsis (1% to 2%; including <i>enterobacter, klebsiella, staphylococcus</i>), bacteremia (1%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Neuromuscular &amp; skeletal: Myalgia (7% to 9%), swelling of extremities (8%), musculoskeletal pain (7%), myasthenia (6%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Renal: Renal failure (4%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Respiratory: Oropharyngeal pain (10%), dyspnea on exertion (7%), pleural effusion (7%), rhinorrhea (5%), pulmonary infection (3%), hypoxia (2%), respiratory distress (1%), respiratory tract infection</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Miscellaneous: Physical health deterioration (2%), troponin increased (troponin I)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Frequency not defined:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Cardiovascular: Angina pectoris, atrial fibrillation (including exacerbation), bradycardia, cardiac disease (aortic disorder), cardiogenic shock, cardiomyopathy, cerebral infarction, cerebrovascular accident, ischemia, ischemic heart disease, myocardial infarction, septic shock, subarachnoid hemorrhage, superficial thrombophlebitis, supraventricular cardiac arrhythmia, supraventricular tachycardia, tachyarrhythmia, thrombosis, transient ischemic attacks, ventricular dysfunction</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Central nervous system: Abnormal gait, aphasia, cerebellar infarction, confusion, depression, dysarthria, falling, impaired consciousness, migraine, spinal cord compression</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Dermatologic: Sweet syndrome</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Endocrine &amp; metabolic: Gout, gouty arthritis, Graves disease, hypernatremia, hypoglycemia</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Gastrointestinal: Biliary obstruction, cholecystitis (may be acute), colonic polyps, diverticulitis, dysphagia, gastritis, gastrointestinal hemorrhage, gastrointestinal reflux disease, infection of mouth, inguinal hernia (obstructive), intestinal obstruction (small intestine), intestinal perforation, irritable bowel syndrome, ischemic colitis, melena, pancreatitis, pseudomembranous colitis</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Genitourinary: Azotemia, hematuria, pelvic pain, perirectal abscess, urosepsis</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Hematologic &amp; oncologic: Acquired blood coagulation disorder, acute leukemia, basal cell carcinoma, bone marrow depression, bronchogenic carcinoma, decreased hemoglobin, hemolysis, hemolytic anemia, malignant lymphoma, malignant neoplasm of lung, myelocytic leukemia (acute), postprocedural hemorrhage, progression of cancer, prostate carcinoma, rectal hemorrhage, splenic infarction, warm antibody immunohemolytic anemia</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Hepatic: Abnormal hepatic function tests (may be transient), hepatic failure</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Hypersensitivity: Transfusion reaction</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Infection: Clostridium infection, fungal infection, herpes virus infection, kidney infection, localized infection, pseudomonas infection, staphylococcal infection</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Local: Catheter infection</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Neuromuscular &amp; skeletal: Arthritis (including exacerbation), bone fracture (femur, femoral neck, pelvis, hip, rib, spinal compression), calcium pyrophosphate deposition disease, neck pain</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Otic: Otic infection</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Renal: Acute renal failure, increased serum creatinine</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Respiratory: Acute sinusitis, chronic obstructive pulmonary disease (includes exacerbation), interstitial pulmonary disease, lobar pneumonia, pulmonary edema, pulmonary infiltrates, respiratory failure, wheezing</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Miscellaneous: Accidental injury (traffic accident), mass (renal), nodule</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">&lt;1%, postmarketing, and/or case reports: Angioedema, cholestatic hepatitis, DRESS syndrome, graft versus host disease, hematologic disease (impaired stem cell mobilization), hepatic cytolysis, hyperthyroidism, organ transplant rejection, pneumonitis, reactivation of disease (HBV, herpes zoster), Stevens-Johnson syndrome, toxic epidermal necrolysis, toxic hepatitis, tumor lysis syndrome</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F2407586\" class=\"block coi drugH1Div\"><span class=\"drugH1\">Contraindications</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Severe hypersensitivity (eg, angioedema, Stevens-Johnson syndrome, toxic epidermal necrolysis) to lenalidomide or any component of the formulation; pregnancy</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <i>Canadian labeling: </i>Additional contraindications (not in the US labeling): Platelet count &lt;50,000/mm<sup>3</sup> (in MDS patients); hypersensitivity to thalidomide or pomalidomide; women capable of becoming pregnant; breastfeeding women; male patients unable to follow or comply with required contraceptive measures</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F2407587\" class=\"block war drugH1Div\"><span class=\"drugH1\">Warnings/Precautions</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Concerns related to adverse effects:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Bone marrow suppression: <b>[US Boxed Warning]: Hematologic toxicity (neutropenia and thrombocytopenia) occurs in a majority of patients (grade 3/4: 80% in patients with del 5q myelodysplastic syndrome) and may require dose reductions and/or delays; the use of blood product support and/or growth factors may be needed. CBC should be monitored weekly for the first 8 weeks and at least monthly thereafter in patients being treated for del 5q myelodysplastic syndromes.</b> In patients being treated for multiple myeloma, monitor CBC weekly for the first 2 cycles, every 2 weeks during cycle 3, and monthly thereafter. In patients receiving lenalidomide for mantle cell lymphoma (MCL), monitor CBC weekly for the first cycle, every 2 weeks during cycles 2 to 4, and monthly thereafter. Monitor for signs of infection, bleeding, or bruising; may require dosage adjustment.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; CNS effects: May cause dizziness or fatigue; caution patients about performing tasks that require mental alertness (eg, operating machinery, driving).</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Dermatologic reactions: Angioedema and severe cutaneous reactions (eg, Stevens-Johnson syndrome [SJS], toxic epidermal necrolysis [TEN], and drug reaction with eosinophilia and systemic symptoms [DRESS]) have been reported; may be fatal. DRESS may manifest as a cutaneous reaction (eg, rash, exfoliative dermatitis), eosinophilia, fever, and/or lymphadenopathy with systemic complications, which may include hepatitis, nephritis, pneumonitis, myocarditis, and/or pericarditis. Consider interrupting or discontinuing treatment with grade 2 or 3 skin rash; discontinue and do not reinitiate treatment with angioedema, grade 4 rash, exfoliative or bullous rash, or for suspected SJS, TEN, or DRESS. Patients with a history of grade 4 rash with thalidomide should not receive lenalidomide.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Hepatotoxicity: Hepatic failure, including fatalities, has occurred in patients treated with combination lenalidomide and dexamethasone therapy; may have hepatocellular, cholestatic, or mixed characteristics. Risk factors may include preexisting viral liver disease, elevated liver enzymes at baseline, and concomitant medications. Monitor closely; interrupt therapy in patients with abnormal hepatic function tests. May consider resuming treatment at a lower dose upon return to baseline.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Secondary malignancy: Second primary malignancies (SPMs), including hematologic (primarily AML and MDS) and solid tumor malignancies, and non-melanoma skin cancers, have been reported with lenalidomide when used for the treatment of MDS and multiple myeloma; the incidence may be higher when lenalidomide is used in combination with an alkylating agent. Monitor for development of secondary malignancies.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Thromboembolic events: <b>[US Boxed Warning]: Lenalidomide has been associated with a significant increase in risk for arterial and venous thromboembolic events in multiple myeloma patients treated with lenalidomide and dexamethasone combination therapy. Deep vein thrombosis (DVT), pulmonary embolism (PE), myocardial infarction, and stroke have occurred; monitor for signs and symptoms of thromboembolism (shortness of breath, chest pain, or arm or leg swelling) and instruct patients to seek prompt medical attention with development of these symptoms. Thromboprophylaxis is recommended; the choice of regimen should be based on an assessment of the patient's underlying risk factors.</b> The American Society of Clinical Oncology guidelines for VTE prophylaxis and treatment recommend thromboprophylaxis for patients receiving lenalidomide in combination with chemotherapy and/or dexamethasone; either aspirin or low molecular weight heparin (LMWH) is recommended for lower risk patients and LMWH is recommended for higher-risk patients (Lyman 2013; Lyman 2015). Erythropoietin-stimulating agents (ESAs) and estrogens may contribute to thromboembolic risk; use with caution. Patients with a prior history of arterial thromboembolic events may be at greater risk; minimize modifiable factors such as hyperlipidemia, hypertension, and smoking. Anticoagulant prophylaxis should be individualized and selected based on the thromboembolism risk of the combination treatment regimen, using the safest and easiest to administer (Palumbo 2008).</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Thyroid disorders: Both hypothyroidism and hyperthyroidism have been reported with lenalidomide use; monitor thyroid function prior to therapy initiation and periodically throughout treatment.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Tumor flare: Observed in studies of lenalidomide for the treatment of chronic lymphocytic leukemia (CLL) and lymphoma; clinical presentation includes low grade fever, pain, rash, and tender lymph node swelling. In patients with mantle cell lymphoma (MCL), tumor flare may mimic disease progression; monitor closely. In clinical trials, the majority of tumor flare events occurred in the first cycle of therapy. Treatment with corticosteroids, nonsteroidal anti-inflammatory drugs (NSAIDs), and/or analgesics may be considered; therapy interruption may be necessary as well.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Tumor lysis syndrome: Patients with a high tumor burden may be at risk for tumor lysis syndrome; monitor closely; institute appropriate management for hyperuricemia. Tumor lysis syndrome (with fatalities) has been reported with lenalidomide.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Disease-related concerns:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Heart failure: In a scientific statement from the American Heart Association, lenalidomide has been determined to be an agent that may either cause direct myocardial toxicity or exacerbate underlying myocardial dysfunction (magnitude: major) (AHA [Page 2016]).</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Mantle cell lymphoma: An increased incidence of early deaths (within 20 weeks) was reported in one study of patients receiving lenalidomide for the treatment of mantle cell lymphoma. Risk factors for early death include high tumor burden, mantle cell lymphoma international prognostic index (MIPI) score at diagnosis, and high WBC count (&ge;10,000/mm<sup>3</sup>) at baseline.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Multiple myeloma: An increase in mortality was noted in 2 clinical studies in patients with multiple myeloma who received pembrolizumab in combination with a thalidomide analogue and dexamethasone. Causes of death in the experimental arm (containing pembrolizumab, dexamethasone, and a thalidomide analogue [pomalidomide or lenalidomide]) included myocarditis, Stevens-Johnson syndrome, MI, pericardial hemorrhage, cardiac failure, respiratory tract infection, neutropenic sepsis, sepsis, multiple organ dysfunction, respiratory failure, intestinal ischemia, cardiopulmonary arrest, suicide, pulmonary embolism, cardiac arrest, pneumonia, sudden death, and large intestine perforation. Multiple myeloma is not an approved indication for PD-1 or PD-L1 blocking antibodies; pembrolizumab should not be used to treat multiple myeloma in combination with a thalidomide analogue and dexamethasone unless as part of a clinical trial.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Renal impairment: Use with caution in patients with renal impairment; may experience an increased rate of toxicities due to reduced clearance and increased half-life. Initial dosage adjustments are recommended for moderate to severe and dialysis-dependent renal impairment.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Stem cell mobilization: Lenalidomide use (&ge;4 cycles) may decrease the number of CD34+ cells collected for autologous stem cell transplant. Transplant eligible patients receiving lenalidomide should be referred to an appropriate transplant center in order to optimize the timing of stem cell collection. Cyclophosphamide in combination with G-CSF or G-CSF in combination with a CXC chemokine receptor 4 inhibitor (eg, plerixafor) may be considered when CD34+ cell collection is impaired.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Concurrent drug therapy issues:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Drug-drug interactions: Potentially significant interactions may exist, requiring dose or frequency adjustment, additional monitoring, and/or selection of alternative therapy. Consult drug interactions database for more detailed information.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Special populations:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Elderly: Certain adverse reactions (DVT, pulmonary embolism, atrial fibrillation, renal failure) are more likely in elderly patients. Monitor renal function closely, and select dose accordingly.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Pediatric: If used in patients between 12 to 18 years of age, the parent or legal guardian must agree to ensure compliance with the Revlimid REMS program.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Pregnancy: <b>[US Boxed Warning]: Do not use lenalidomide in pregnant women. Lenalidomide is an analogue of thalidomide (a human teratogen) and could potentially cause severe birth defects or embryo-fetal death; use is contraindicated during pregnancy and pregnancy must be avoided while taking lenalidomide. Obtain 2 negative pregnancy tests prior to initiation of treatment; 2 forms of contraception (or abstain from heterosexual intercourse) must be used at least 4 weeks prior to, during and for 4 weeks after lenalidomide treatment (and during treatment interruptions). In order to decrease the risk of embryo-fetal exposure, lenalidomide is available only through a restricted distribution program (Revlimid REMS).</b> Males taking lenalidomide (even those vasectomized) must use a latex or synthetic condom during any sexual contact with women of reproductive potential and for up to 28 days following discontinuation of therapy. Males taking lenalidomide must not donate sperm.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Other warnings/precautions:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Appropriate use: In a clinical trial comparing lenalidomide versus chlorambucil single agent therapy in patients &gt;65 years of age with chronic lymphocytic leukemia patients (not an FDA-approved indication), increased mortality was observed in the lenalidomide treatment arm. Atrial fibrillation, cardiac failure, and MI were observed more frequently in lenalidomide-treated patients; lenalidomide (alone or in combination) is not currently recommended for first-line treatment of CLL.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; REMS program: Due to the embryo-fetal risk, lenalidomide is only available through a restricted program under the Revlimid REMS program. Prescribers and pharmacies must be certified with the program to prescribe or dispense lenalidomide. Lenalidomide should only be prescribed to patients (male and female) who can understand and comply with the conditions of the Revlimid REMS program.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Blood donation: Patients should be advised not to donate blood during therapy and for 1 month following completion of therapy.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Lactose intolerance: Product may contain lactose; avoid use in patients with Lapp lactase deficiency, glucose-galactose malabsorption, or glucose intolerance.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F13299581\" class=\"block cyt drugH1Div\"><span class=\"drugH1\">Metabolism/Transport Effects</span>\n    <p style=\"text-indent:0em;display:inline\">\n      <b>Substrate</b> of P-glycoprotein/ABCB1</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F2407598\" class=\"block dri drugH1Div\"><span class=\"drugH1\">Drug Interactions</span>\n    <br/><br/><div id=\"lexiInteractAddInfo\" class=\"lexi\">(For additional information: <a href=\"https://www.uptodate.com/drug-interactions/?search=&amp;topicId=9822&amp;source=responsive_topic\" class=\"dip\" target=\"_blank\">Launch drug interactions program</a>)</div><div id=\"lexiInteractImgB\" class=\"lexi\"><img src=\"/images/lexiComp/Lexicomp_2012_71x17.gif\" width=\"71\" height=\"17\" border=\"0\"/></div><div class=\"clear\"></div><p style=\"text-indent:-2em;margin-left:2em;\">Abatacept: Anti-TNF Agents may enhance the adverse/toxic effect of Abatacept. An increased risk of serious infection during concomitant use has been reported. <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Anakinra: Anti-TNF Agents may enhance the adverse/toxic effect of Anakinra. An increased risk of serious infection during concomitant use has been reported. <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">BCG (Intravesical): Immunosuppressants may diminish the therapeutic effect of BCG (Intravesical). <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">BCG (Intravesical): Myelosuppressive Agents may diminish the therapeutic effect of BCG (Intravesical). <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Bisphosphonate Derivatives: Angiogenesis Inhibitors (Systemic) may enhance the adverse/toxic effect of Bisphosphonate Derivatives. Specifically, the risk for osteonecrosis of the jaw may be increased. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Canakinumab: Anti-TNF Agents may enhance the adverse/toxic effect of Canakinumab. Specifically, the risk for serious infections and/or neutropenia may be increased. <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Certolizumab Pegol: Anti-TNF Agents may enhance the immunosuppressive effect of Certolizumab Pegol. <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Chloramphenicol (Ophthalmic): May enhance the adverse/toxic effect of Myelosuppressive Agents.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">CloZAPine: Myelosuppressive Agents may enhance the adverse/toxic effect of CloZAPine. Specifically, the risk for neutropenia may be increased. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Coccidioides immitis Skin Test: Immunosuppressants may diminish the diagnostic effect of Coccidioides immitis Skin Test. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Deferiprone: Myelosuppressive Agents may enhance the neutropenic effect of Deferiprone. <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Denosumab: May enhance the adverse/toxic effect of Immunosuppressants. Specifically, the risk for serious infections may be increased.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Dexamethasone (Systemic): May enhance the thrombogenic effect of Lenalidomide.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Digoxin: Lenalidomide may increase the serum concentration of Digoxin. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Dipyrone: May enhance the adverse/toxic effect of Myelosuppressive Agents. Specifically, the risk for agranulocytosis and pancytopenia may be increased<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Echinacea: May diminish the therapeutic effect of Immunosuppressants.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Erythropoiesis-Stimulating Agents: May enhance the thrombogenic effect of Lenalidomide.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Estrogen Derivatives: May enhance the thrombogenic effect of Lenalidomide.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Fingolimod: Immunosuppressants may enhance the immunosuppressive effect of Fingolimod.  Management: Avoid the concomitant use of fingolimod and other immunosuppressants when possible. If combined, monitor patients closely for additive immunosuppressant effects (eg, infections).<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Leflunomide: Immunosuppressants may enhance the adverse/toxic effect of Leflunomide. Specifically, the risk for hematologic toxicity such as pancytopenia, agranulocytosis, and/or thrombocytopenia may be increased.  Management: Consider not using a leflunomide loading dose in patients receiving other immunosuppressants.  Patients receiving both leflunomide and another immunosuppressant should be monitored for bone marrow suppression at least monthly.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Natalizumab: Immunosuppressants may enhance the adverse/toxic effect of Natalizumab. Specifically, the risk of concurrent infection may be increased. <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Nivolumab: Immunosuppressants may diminish the therapeutic effect of Nivolumab. <i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Ocrelizumab: May enhance the immunosuppressive effect of Immunosuppressants.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Pembrolizumab: May enhance the adverse/toxic effect of Thalidomide Analogues. Specifically, mortality may be increased when this combination is used for treatment of refractory multiple myeloma.<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Pidotimod: Immunosuppressants may diminish the therapeutic effect of Pidotimod. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Pimecrolimus: May enhance the adverse/toxic effect of Immunosuppressants.<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Promazine: May enhance the myelosuppressive effect of Myelosuppressive Agents.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Rilonacept: Anti-TNF Agents may enhance the adverse/toxic effect of Rilonacept. <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Roflumilast: May enhance the immunosuppressive effect of Immunosuppressants.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Sipuleucel-T: Immunosuppressants may diminish the therapeutic effect of Sipuleucel-T. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Tacrolimus (Topical): May enhance the adverse/toxic effect of Immunosuppressants.<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Tertomotide: Immunosuppressants may diminish the therapeutic effect of Tertomotide. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Tocilizumab: May enhance the immunosuppressive effect of Anti-TNF Agents.<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Tofacitinib: Anti-TNF Agents may enhance the adverse/toxic effect of Tofacitinib. <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Trastuzumab: May enhance the neutropenic effect of Immunosuppressants.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Vaccines (Inactivated): Immunosuppressants may diminish the therapeutic effect of Vaccines (Inactivated).  Management: Vaccine efficacy may be reduced. Complete all age-appropriate vaccinations at least 2 weeks prior to starting an immunosuppressant. If vaccinated during immunosuppressant therapy, revaccinate at least 3 months after immunosuppressant discontinuation.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Vaccines (Live): Immunosuppressants may enhance the adverse/toxic effect of Vaccines (Live). Immunosuppressants may diminish the therapeutic effect of Vaccines (Live).  Management: Avoid use of live organism vaccines with immunosuppressants; live-attenuated vaccines should not be given for at least 3 months after immunosuppressants.<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Vedolizumab: Anti-TNF Agents may enhance the adverse/toxic effect of Vedolizumab. <i> Risk X: Avoid combination</i></p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F2407581\" class=\"block pri drugH1Div\"><span class=\"drugH1\">Pregnancy Implications</span>\n    <p style=\"text-indent:0em;\">\n      <b>[US Boxed Warning]: Do not use lenalidomide in pregnant women. Lenalidomide is an analogue of thalidomide (a human teratogen) and could potentially cause severe birth defects or embryo-fetal death; use is contraindicated during pregnancy and pregnancy must be avoided while taking lenalidomide. Obtain 2 negative pregnancy tests prior to initiation of treatment; 2 forms of contraception (or abstain from heterosexual intercourse) must be used at least 4 weeks prior to, during, and for 4 weeks after lenalidomide treatment (and during treatment interruptions). In order to decrease the risk of embryo-fetal exposure, lenalidomide is available only through a restricted distribution program (Revlimid REMS). </b></p>\n    <p style=\"text-indent:0em;margin-top:2em;\">Women of reproductive potential should be treated only if they are able to comply with the conditions of the Revlimid REMS program. Women of reproductive potential must avoid pregnancy beginning 4 weeks prior to therapy, during therapy, during therapy interruptions, and for at least 4 weeks after therapy is discontinued. Two forms of effective/reliable contraception (eg, tubal ligation, IUD, hormonal birth control methods, male latex or synthetic condom, diaphragm, or cervical cap) or total abstinence from heterosexual intercourse must be used by females who are not infertile or who have not had a hysterectomy. A negative pregnancy test (sensitivity of at least 50 milliunits/mL) 10 to 14 days prior to therapy, within 24 hours prior to beginning therapy, weekly during the first 4 weeks, and every 4 weeks (every 2 weeks for women with irregular menstrual cycles) thereafter is required for women of reproductive potential. Lenalidomide must be immediately discontinued for a missed period, abnormal pregnancy test or abnormal menstrual bleeding; refer patient to a reproductive toxicity specialist if pregnancy occurs during treatment.</p>\n    <p style=\"text-indent:0em;margin-top:2em;\">Lenalidomide is also present in the semen of males. Males (including those vasectomized) should use a latex or synthetic condom during any sexual contact with women of reproductive age during treatment, during treatment interruptions, and for 4 weeks after discontinuation. Male patients should not donate sperm during, and for 4 weeks after treatment, and during therapy interruptions.</p>\n    <p style=\"text-indent:0em;margin-top:2em;\">A pregnancy exposure registry has been created to monitor outcomes in females exposed to lenalidomide during pregnancy and female partners of male patients and to understand the root cause for the pregnancy. The pregnancy exposure registry may be contacted at 1-888-423-5436. The parent or legal guardian for patients between 12 and 18 years of age must agree to ensure compliance with the required guidelines. Any suspected fetal exposure should be reported to the FDA via the MedWatch program (1-800-FDA-1088) and to Celgene Corporation (1-888-423-5436).</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F2407585\" class=\"block brc drugH1Div\"><span class=\"drugH1\">Breast-Feeding Considerations</span>\n    <p style=\"text-indent:0em;display:inline\">It is not known if lenalidomide is present in breast milk. Due to the potential for serious adverse reactions in the infant, breastfeeding is not recommended by the manufacturer.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F2407617\" class=\"block mop drugH1Div\"><span class=\"drugH1\">Monitoring Parameters</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">CBC with differential (MCL - weekly for the first cycle, every 2 weeks during cycles 2 to 4; MDS - weekly for first 8 weeks; Multiple myeloma - weekly for the first 2 cycles, every 2 weeks during the third cycle), then monthly thereafter; serum creatinine, liver function tests, thyroid function tests (TSH at baseline then every 2 to 3 months during lenalidomide treatment [Hamnvik 2011]); ECG when clinically indicated; monitor for signs and symptoms of infection (if neutropenic), secondary malignancies, thromboembolism, dermatologic toxicity, tumor lysis syndrome, or tumor flare reaction.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Women of reproductive potential: Pregnancy test 10 to 14 days <b>and</b> 24 hours prior to initiating therapy, weekly during the first 4 weeks of treatment, then every 2 to 4 weeks through 4 weeks after therapy discontinued.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Monitor adherence.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F2407602\" class=\"block pha drugH1Div\"><span class=\"drugH1\">Mechanism of Action</span>\n    <p style=\"text-indent:0em;display:inline\">Lenalidomide has immunomodulatory, antiangiogenic, and antineoplastic characteristics via multiple mechanisms. It selectively inhibits secretion of proinflammatory cytokines (potent inhibitor of tumor necrosis factor-alpha secretion); enhances cell-mediated immunity by stimulating proliferation of anti-CD3 stimulated T cells (resulting in increased IL-2 and interferon gamma secretion); inhibits trophic signals to angiogenic factors in cells. Inhibits the growth of myeloma cells by inducing cell cycle arrest and cell death.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F2407604\" class=\"block phk drugH1Div\"><span class=\"drugH1\">Pharmacodynamics/Kinetics</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Absorption: Rapid</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Protein binding: ~30%</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Half-life elimination: 3 to 5 hours</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Time, to peak, plasma: MDS or myeloma patients: 0.5 to 6 hours</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Excretion: Urine (~82%; as unchanged drug)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Hemodialysis effect: ~30% of the drug in body is removed in a 4-hour hemodialysis session; Hemodialysis patients: 80% decrease in drug clearance compared with healthy subjects.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F16322927\" class=\"block fee drugH1Div\"><span class=\"drugH1\">Pricing: US</span>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Capsules</b> (Revlimid Oral)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">2.5 mg (28): $22,255.28</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">5 mg (28): $22,255.28</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">10 mg (28): $22,255.28</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">15 mg (21): $16,691.48</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">20 mg (21): $16,691.48</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">25 mg (21): $16,691.48</p>\n    <p style=\"text-indent:0em;\">\n      <b>Disclaimer: </b>A representative AWP (Average Wholesale Price) price or price range is provided as reference price only. A range is provided when more than one manufacturer's AWP price is available and uses the low and high price reported by the manufacturers to determine the range. The pricing data should be used for benchmarking purposes only, and as such should not be used alone to set or adjudicate any prices for reimbursement or purchasing functions or considered to be an exact price for a single product and/or manufacturer.  Medi-Span expressly disclaims all warranties of any kind or nature, whether express or implied, and assumes no liability with respect to accuracy of price or price range data published in its solutions.  In no event shall Medi-Span be liable for special, indirect, incidental, or consequential damages arising from use of price or price range data.  Pricing data is updated monthly.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F5539966\" class=\"list fbnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: International</span>\n    <ul>\n      <li>Ladevina (AR, VN);</li>\n      <li>Lenangio (IN);</li>\n      <li>Linamide (BD);</li>\n      <li>Revlimid (AE, AT, AU, BB, BE, CH, CL, CR, CY, CZ, DE, DK, DO, EC, EE, ES, FR, GB, GR, GT, HK, HN, HR, HU, IE, IL, IS, IT, JO, JP, KR, KW, LB, LT, LU, LV, MT, MX, MY, NI, NL, NO, NZ, PA, PE, PH, PL, PT, QA, RO, RU, SE, SG, SI, SK, SV, TH, TR)</li></ul></div>\r\n</div><div id=\"topicAgreement\">Use of UpToDate is subject to the <a href=\"https://www.uptodate.com/legal/license\" class=\"licenseLink\" id=\"sla_in_page\">Subscription and License Agreement</a>.</div><div id=\"references\" class=\"headingAnchor\"><h1>REFERENCES</h1><ol id=\"reference\">\r\n<li>\r\n<div class=\"reference\">\n    &lt;800&gt; Hazardous Drugs&mdash;Handling in Healthcare Settings. <i>United States Pharmacopeia and National Formulary</i> (USP 40-NF 35). Rockville, MD: United States Pharmacopeia Convention; 2017:83-102.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    \n      <a name=\"22571202\"></a>Attal M, Lauwers-Cances V, Marit G, et al. Lenalidomide Maintenance After Stem-Cell Transplantation for Multiple Myeloma. <i>N Engl J Med.</i> 2012;366(19):1782-1791.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/lenalidomide-drug-information/abstract-text/22571202/pubmed\" target=\"_blank\" id=\"22571202\">22571202</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    \n      <a name=\"23270003\"></a>Badoux XC, Keating MJ, Wen S, et al, &ldquo;Phase II Study of Lenalidomide and Rituximab as Salvage Therapy for Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia,&rdquo; <i>J Clin Oncol</i>, 2013, 31(5):584-91.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/lenalidomide-drug-information/abstract-text/23270003/pubmed\" target=\"_blank\" id=\"23270003\">23270003</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Barlogie B, Shaughnessy J, Tricot G, et al, &ldquo;Treatment of Multiple Myeloma,&rdquo; <i>Blood</i>, 2004, 103(1):20-32.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/lenalidomide-drug-information/abstract-text/12969978/pubmed\" target=\"_blank\" id=\"12969978\">12969978</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Chanan-Khan A, Miller KC, Musial L, et al, &ldquo;Clinical Efficacy of Lenalidomide in Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia: Results of a Phase II Study,&rdquo; <i>J Clin Oncol</i>, 2006, 24(34):5343-9.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/lenalidomide-drug-information/abstract-text/17088571/pubmed\" target=\"_blank\" id=\"17088571\">17088571</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Chen N, Kasserra C, Reyes J, et al, &ldquo;Single-dose Pharmacokinetics of Lenalidomide in Healthy Volunteers: Dose Proportionality, Food Effect, and Racial Sensitivity,&rdquo; <i>Cancer Chemother Pharmacol</i>, 2012, 70(5):717-25.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/lenalidomide-drug-information/abstract-text/22955172/pubmed\" target=\"_blank\" id=\"22955172\">22955172</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Chen N, Lau H, Kong L, et al, &ldquo;Pharmacokinetics of Lenalidomide in Subjects With Various Degrees of Renal Impairment and in Subjects on Hemodialysis,&rdquo; <i>J Clin Pharmacol</i>, 2007, 47(12):1466-75.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/lenalidomide-drug-information/abstract-text/17954615/pubmed\" target=\"_blank\" id=\"17954615\">17954615</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Dimopoulos M, Alegre A, Stadtmauer EA et al, &ldquo;The Efficacy and Safety of Lenalidomide Plus Dexamethasone in Relapsed and/or Refractory Multiple Myeloma Patients With Impaired Renal Function,&rdquo; <i>Cancer</i>, 2010, 116(16):3807-14.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/lenalidomide-drug-information/abstract-text/20564094/pubmed\" target=\"_blank\" id=\"20564094\">20564094</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Dimopoulos MA, Anagnostopoulos A, and Weber D, &ldquo;Treatment of Plasma Cell Dyscrasias With Thalidomide and Its Derivatives,&rdquo; <i>J Clin Oncol</i>, 2003, 21(23):4444-54.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/lenalidomide-drug-information/abstract-text/14645435/pubmed\" target=\"_blank\" id=\"14645435\">14645435</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Dimopoulos MA, Oriol A, Nahi H, et al. Daratumumab, lenalidomide, and dexamethasone for multiple myeloma. <i>N Engl J Med</i>. 2016a;375(14):1319-1331.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/lenalidomide-drug-information/abstract-text/27705267/pubmed\" target=\"_blank\" id=\"27705267\">27705267</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Dimopoulos MA, Richardson PG, Brandenburg N, et al, &ldquo;A Review of Second Primary Malignancy in Patients With Relapsed or Refractory Multiple Myeloma Treated With Lenalidomide,&rdquo; <i>Blood</i>, 2012, 9(12):2764-7.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/lenalidomide-drug-information/abstract-text/22323483/pubmed\" target=\"_blank\" id=\"22323483\">22323483</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Dimopoulos MA, Sonneveld P, Leung N, et al. International Myeloma Working Group recommendations for the diagnosis and management of myeloma-related renal impairment. <i>J Clin Oncol</i>. 2016b;34(13):1544-1557.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/lenalidomide-drug-information/abstract-text/26976420/pubmed\" target=\"_blank\" id=\"26976420\">26976420</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Dimopoulos M, Spencer A, Attal M, et al, &ldquo;Lenalidomide Plus Dexamethasone for Relapsed or Refractory Multiple Myeloma,&rdquo; <i>N Engl J Med</i>, 2007, 357(21):2123-32.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/lenalidomide-drug-information/abstract-text/18032762/pubmed\" target=\"_blank\" id=\"18032762\">18032762</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Dispenzieri A, Lacy MQ, Zeldenrust SR, et al, &ldquo;The Activity of Lenalidomide With or Without Dexamethasone in Patients With Primary Systemic Amyloidosis,&rdquo; <i>Blood</i>, 2007, 109(2):465-70.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/lenalidomide-drug-information/abstract-text/17008538/pubmed\" target=\"_blank\" id=\"17008538\">17008538</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Eve HE and Rule SA, &ldquo;Lenalidomide-Induced Tumour Flare Reaction In Mantle Cell Lymphoma,&rdquo; <i>Br J Haematol</i>, 2010, 151(4):410-2.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/lenalidomide-drug-information/abstract-text/20880113/pubmed\" target=\"_blank\" id=\"20880113\">20880113</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Faderl S and Kantarjian HM, &ldquo;Novel Therapies for Myelodysplastic Syndromes,&rdquo; <i>Cancer</i>, 2004, 101(2): 226-41.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Fenaux P, Giagounidis A, Selleslag D, et al, &ldquo;A Randomized Phase 3 Study of Lenalidomide versus Placebo in RBC Transfusion-Dependent Patients With Low-/Intermediate-1-Risk Myelodysplastic Syndromes With del5q,&rdquo; <i>Blood</i>, 2011, 118(14):3765-76.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/lenalidomide-drug-information/abstract-text/21753188/pubmed\" target=\"_blank\" id=\"21753188\">21753188</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Ferrajoli A, Lee BN, Schlette EJ, et al, &ldquo;Lenalidomide Induces Complete and Partial Remissions in Patients With Relapsed and Refractory Chronic Lymphocytic Leukemia,&rdquo; <i>Blood</i>, 2008, 111(11): 5291-7.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/lenalidomide-drug-information/abstract-text/18334676/pubmed\" target=\"_blank\" id=\"18334676\">18334676</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Giagounidis AA, Germing U, Strupp C, et al, &ldquo;Prognosis of Patients with del(5q) MDS and Complex Karotype and the Possible Role of Lenalidomide in this Patient Subgroup,&rdquo; <i>Ann Hematol</i>, 2005, 84(9):569-71.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/lenalidomide-drug-information/abstract-text/15891887/pubmed\" target=\"_blank\" id=\"15891887\">15891887</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Giagoundis A, Raza A, List AF, et al, &ldquo;Analysis of Second Primary Malignancies in Lenalidomide-Treated Patients with IPSS Low- or Int-1-Risk Myelodysplastic Syndromes,&rdquo; <i>Blood</i>, 2011, 118(21):1704 [abstract 1704 from 2011 ASH Annual Meeting]</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Goy A, Sinha R, Williams ME, et al. Single-agent lenalidomide in patients with mantle-cell lymphoma who relapsed or progressed after or were refractory to bortezomib: phase II MCL-001 (EMERGE) study. <i>J Clin Oncol</i>. 2013;31(29):3688-3695.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/lenalidomide-drug-information/abstract-text/24002500/pubmed\" target=\"_blank\" id=\"24002500\">24002500</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Habermann TM, Lossos IS, Justice G, et al, &ldquo;Lenalidomide Oral Monotherapy Produces a High Response Rate in Patients With Relapsed or Refractory Mantle Cell Lymphoma,&rdquo; <i>Br J Haematol</i>, 2009, 145(3):344-9.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/lenalidomide-drug-information/abstract-text/19245430/pubmed\" target=\"_blank\" id=\"19245430\">19245430</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Hamnvik OP, Larsen PR, and Marqusee E, &ldquo;Thyroid Dysfunction From Antineoplastic Agents,&rdquo; <i>J Natl Cancer Inst</i>, 2011, 103(21):1572-87.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/lenalidomide-drug-information/abstract-text/22010182/pubmed\" target=\"_blank\" id=\"22010182\">22010182</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Jakubowiak AJ, Dytfeld D, Griffith KA, et al. A phase 1/2 study of carfilzomib in combination with lenalidomide and low-dose dexamethasone as a frontline treatment for multiple myeloma. <i>Blood.</i> 2012;120(9):1801-1809.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/lenalidomide-drug-information/abstract-text/22665938/pubmed\" target=\"_blank\" id=\"22665938\">22665938</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    \n      <a name=\"22422823\"></a>Kumar S, Flinn I, Richardson PG, et al, &ldquo;Randomized, Multicenter, Phase 2 Study (EVOLUTION) of Combinations of Bortezomib, Dexamethasone, Cyclophosphamide, and Lenalidomide in Previously Untreated Multiple Myeloma,&rdquo; <i>Blood</i>, 2012, 119(19):4375-82.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/lenalidomide-drug-information/abstract-text/22422823/pubmed\" target=\"_blank\" id=\"22422823\">22422823</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Kyle RA and Rajkumar SV, &ldquo;Multiple Myeloma,&rdquo; <i>N Engl J Med</i>, 2004, 351(18):1860-73.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/lenalidomide-drug-information/abstract-text/15509819/pubmed\" target=\"_blank\" id=\"15509819\">15509819</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Larocca A, Cavallo F, Bringhen S, et al, &ldquo;Aspirin or Enoxaparin Thromboprophylaxis for Patients With Newly Diagnosed Multiple Myeloma Treated With Lenalidomide,&rdquo; <i>Blood</i>, 2012, 119(4):933-9.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/lenalidomide-drug-information/abstract-text/21835953/pubmed\" target=\"_blank\" id=\"21835953\">21835953</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    List A, Dewald G, Bennett J, et al, &ldquo;Lenalidomide in Myelodysplastic Syndrome With Chromosome 5q Deletion,&rdquo; <i>N Engl J Med</i>, 2006, 355(14):1456-65.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/lenalidomide-drug-information/abstract-text/17021321/pubmed\" target=\"_blank\" id=\"17021321\">17021321</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    List A, Kurtin S, Roe DJ, et al, &ldquo;Efficacy of Lenalidomide in Myelodysplastic Syndromes,&rdquo; <i>N Engl J Med</i>, 2005, 352(6):549-57.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/lenalidomide-drug-information/abstract-text/15703420/pubmed\" target=\"_blank\" id=\"15703420\">15703420</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Lyman GH, Bohlke K, Khorana AA, et al; American Society of Clinical Oncology. Venous thromboembolism prophylaxis and treatment in patients with cancer: American Society of Clinical Oncology clinical practice guideline update 2014. <i>J Clin Oncol</i>. 2015;33(6):654-656. doi: 10.1200/JCO.2014.59.7351.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/lenalidomide-drug-information/abstract-text/25605844/pubmed\" target=\"_blank\" id=\"25605844\">25605844</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Lyman GH, Khorana AA, Kuderer NM, et al; American Society of Clinical Oncology Clinical Practice. Venous thromboembolism prophylaxis and treatment in patients with cancer: American Society of Clinical Oncology clinical practice guideline update. <i>J Clin Oncol</i>. 2013;31(17):2189-2204. doi: 10.1200/JCO.2013.49.1118.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/lenalidomide-drug-information/abstract-text/23669224/pubmed\" target=\"_blank\" id=\"23669224\">23669224</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    \n      <a name=\"22571201\"></a>McCarthy PL, Owzar K, Hofmeister CC, et al, &ldquo;Lenalidomide After Stem-Cell Transplantation for Multiple Myeloma,&rdquo; <i>N Engl J Med</i>, 2012, 366(19):1770-81.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/lenalidomide-drug-information/abstract-text/22571201/pubmed\" target=\"_blank\" id=\"22571201\">22571201</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Moreau P, Jaccard A, Benboubker L, et al, &ldquo;Lenalidomide in Combination With Melphalan and Dexamethasone in Patients With Newly Diagnosed AL Amyloidosis: A Multicenter Phase 1/2 Dose-Escalation Study,&rdquo; <i>Blood</i>, 2010, 116(23):4777-82.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/lenalidomide-drug-information/abstract-text/20724537/pubmed\" target=\"_blank\" id=\"20724537\">20724537</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    \n      <a name=\"Nair.2012\"></a>Nair D, Sanchorawala V, Shelton AC, et al, &ldquo;Lenalidomide and Dexamethasone in the Treatment of AL Amyloidosis: Final Results of a Phase II Trial,&rdquo; <i>Blood</i>, 2012, 120(21):4084 [abstract 4084 from 2012 ASH Annual Meeting)</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Oehrlein K, Langer C, Sturm I, et al, &ldquo;Successful Treatment of Patients With Multiple Myeloma and Impaired Renal Function With Lenalidomide: Results of 4 German Centers,&rdquo; <i>Clin Lymphoma Myeloma Leuk</i>, 2012, 12(3):191-6.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/lenalidomide-drug-information/abstract-text/22341857/pubmed\" target=\"_blank\" id=\"22341857\">22341857</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Page RL 2nd, O'Bryant CL, Cheng D, et al; American Heart Association Clinical Pharmacology and Heart Failure and Transplantation Committees of the Council on Clinical Cardiology; Council on Cardiovascular Surgery and Anesthesia; Council on Cardiovascular and Stroke Nursing; and Council on Quality of Care and Outcomes Research. Drugs That May Cause or Exacerbate Heart Failure: A Scientific Statement From the American Heart Association [published correction appears in <i>Circulation</i>. 2016;134(12):e261]. <i>Circulation</i>. 2016;134(6):e32-e69.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/lenalidomide-drug-information/abstract-text/27400984/pubmed\" target=\"_blank\" id=\"27400984\">27400984</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    \n      <a name=\"20048187\"></a>Palumbo A, Gay F, Falco P, et al, &ldquo;Bortezomib as Induction Before Autologous Transplantation, Followed by Lenalidomide as Consolidation-Maintenance in Untreated Multiple Myeloma Patients,&rdquo; <i>J Clin Oncol</i>, 2010, 28(5):800-7.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/lenalidomide-drug-information/abstract-text/20048187/pubmed\" target=\"_blank\" id=\"20048187\">20048187</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Palumbo A, Hajek R, Delforge M, et al, &ldquo;Continuous Lenalidomide Treatment for Newly Diagnosed Multiple Myeloma,&rdquo; <i>N Engl J Med</i>, 2012, 366(19):1759-69.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/lenalidomide-drug-information/abstract-text/22571200/pubmed\" target=\"_blank\" id=\"22571200\">22571200</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Palumbo A, Larocca A, Zweegman S, et al, &ldquo;Second Primary Malignancies in Newly Diagnosed Multiple Myeloma Patients Treated with Lenalidomide: Analysis of Pooled Data in 2459 Patients,&rdquo; <i>Blood</i>, 2011, 118(21):996 [abstract 996 from 2011 ASH Annual Meeting]</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Palumbo A, Rajkumar SV, Dimopoulos MA, et al, &ldquo;Prevention of Thalidomide- and Lenalidomide-Associated Thrombosis in Myeloma,&rdquo; <i>Leukemia</i>, 2008, 22(2):414-23.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/lenalidomide-drug-information/abstract-text/18094721/pubmed\" target=\"_blank\" id=\"18094721\">18094721</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Rajkumar SV, Hayman SR, Lacy MQ, et al, &ldquo;Combination Therapy With Lenalidomide Plus Dexamethasone (Rev/Dex) for Newly Diagnosed Myeloma,&rdquo; <i>Blood</i>, 2005, 106(13):4050-3.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/lenalidomide-drug-information/abstract-text/16118317/pubmed\" target=\"_blank\" id=\"16118317\">16118317</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    \n      <a name=\"17893227\"></a>Raza A, Reeves JA, Feldman JA, et al, &ldquo;Phase 2 Study of Lenalidomide in Transfusion-Dependent, Low-Risk, and Intermediate-1 Risk Myelodysplastic Syndromes With Karyotypes Other than Deletion 5q,&rdquo; <i>Blood</i>, 2008, 111(1):86-93.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/lenalidomide-drug-information/abstract-text/17893227/pubmed\" target=\"_blank\" id=\"17893227\">17893227</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Revlimid (lenalidomide) [prescribing information]. Summit, NJ: Celgene Corporation; December 2017.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Revlimid (lenalidomide) [product monograph]. Mississauga, Ontario, Canada: Celgene Inc; October 2017.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Richardson PG, Schlossman RL, Weller E, et al, &ldquo;Immunomodulatory Drug CC-5013 Overcomes Drug Resistance and Is Well Tolerated in Patients With Relapsed Multiple Myeloma,&rdquo; <i>Blood</i>, 2002, 100(9):3063-7.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/lenalidomide-drug-information/abstract-text/12384400/pubmed\" target=\"_blank\" id=\"12384400\">12384400</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    \n      <a name=\"20385792\"></a>Richardson PG, Weller E, Lonial S, et al, &ldquo;Lenalidomide, Bortezomib, and Dexamethasone Combination Therapy in Patients With Newly Diagnosed Multiple Myeloma,&rdquo; <i>Blood</i>, 2010, 116(5):679-86.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/lenalidomide-drug-information/abstract-text/20385792/pubmed\" target=\"_blank\" id=\"20385792\">20385792</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Ruan J, Martin P, Shah B, et al. Lenalidomide plus rituximab as initial treatment for mantle-cell lymphoma. <i>N Engl J Med</i>. 2015;373(19):1835-1844.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/lenalidomide-drug-information/abstract-text/26535512/pubmed\" target=\"_blank\" id=\"26535512\">26535512</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Sanchorawala V, Finn KT, Fennessey S, et al, &ldquo;Durable Hematologic Complete Responses Can Be Achieved With Lenalidomide in AL Amyloidosis,&rdquo; <i>Blood</i>, 2010, 116(11):1990-1.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/lenalidomide-drug-information/abstract-text/20847211/pubmed\" target=\"_blank\" id=\"20847211\">20847211</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    \n      <a name=\"16960148\"></a>Sanchorawala V, Wright DG, Rosenzweig M, et al, &ldquo;Lenalidomide and Dexamethasone in the Treatment of AL Amyloidosis: Results of a Phase 2 Trial,&rdquo; <i>Blood</i>, 2007, 109(2):492-6.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/lenalidomide-drug-information/abstract-text/16960148/pubmed\" target=\"_blank\" id=\"16960148\">16960148</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Stewart AK, Rajkumar SV, Dimopoulos MA, et al. Carfilzomib, lenalidomide, and dexamethasone for relapsed multiple myeloma. <i>N Engl J Med</i>. 2015;372(2):142-152.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/lenalidomide-drug-information/abstract-text/25482145/pubmed\" target=\"_blank\" id=\"25482145\">25482145</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Strati P, Keating MJ, Wierda WG, et al. Lenalidomide induces long-lasting responses in elderly patients with chronic lymphocytic leukemia. <i>Blood</i>. 2013;122(5):734-737.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/lenalidomide-drug-information/abstract-text/23810633/pubmed\" target=\"_blank\" id=\"23810633\">23810633</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Teo SK, &ldquo;Properties of Thalidomide and Its Analogues: Implications for Anticancer Therapy&rdquo; <i>AAPSJ</i>, 2005, 7(1):e14-9.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/lenalidomide-drug-information/abstract-text/16146335/pubmed\" target=\"_blank\" id=\"16146335\">16146335</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    US Department of Health and Human Services; Centers for Disease Control and Prevention; National Institute for Occupational Safety and Health. NIOSH list of antineoplastic and other hazardous drugs in healthcare settings 2016. <a href=\"http://www.cdc.gov/niosh/topics/antineoplastic/pdf/hazardous-drugs-list_2016-161.pdf\" target=\"_blank\">http://www.cdc.gov/niosh/topics/antineoplastic/pdf/hazardous-drugs-list_2016-161.pdf</a>. Updated September 2016. Accessed October 5, 2016.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Usmani S, Sexton R, Hoering A, et al, &ldquo;Second Malignancies in Total Therapy 3 Trials for Newly Diagnosed Multiple Myeloma: Influence of Lenalidomide versus Thalidomide in Maintenance Phases,&rdquo; <i>Blood</i>, 2011, 118(21):823 [abstract 823 from 2011 ASH Annual Meeting]</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Wang M, Fayad L, Wagner-Bartak N, et al, &ldquo;Lenalidomide In Combination With Rituximab for Patients With Relapsed or Refractory Mantle-Cell Lymphoma: A Phase 1/2 Clinical Trial,&rdquo; <i>Lancet Oncol</i>, 2012, 13(7):716-23.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/lenalidomide-drug-information/abstract-text/22677155/pubmed\" target=\"_blank\" id=\"22677155\">22677155</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Weber DM, Chen C, Niesvizky R, et al, &ldquo;Lenalidomide Plus Dexamethasone for Relapsed Multiple Myeloma in North America,&rdquo; <i>N Engl J Med</i>, 2007, 357(21):2133-42.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/lenalidomide-drug-information/abstract-text/18032763/pubmed\" target=\"_blank\" id=\"18032763\">18032763</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    \n      <a name=\"18606983\"></a>Wiernik PH, Lossos IS, Tuscano JM, et al, &ldquo;Lenalidomide Monotherapy in Relapsed or Refractory Aggressive Non-Hodgkin's Lymphoma,&rdquo; <i>J Clin Oncol</i>, 2008, 26(30):4952-7.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/lenalidomide-drug-information/abstract-text/18606983/pubmed\" target=\"_blank\" id=\"18606983\">18606983</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Zinzani PL, Vose JM, Czuczman MS, et al. Long-term follow-up of lenalidomide in relapsed/refractory mantle cell lymphoma: subset analysis of the NHL-003 study. <i>Ann Oncol</i>. 2013;24(11):2892-2897.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/lenalidomide-drug-information/abstract-text/24030098/pubmed\" target=\"_blank\" id=\"24030098\">24030098</a>]</span></div>\r\n</li></ol></div><div id=\"topicVersionRevision\">Topic 9822 Version 169.0</div></div>","outline":"<div id=\"outlineSections\"><h2>Topic Outline</h2><ul><li class=\"plainItem\"><a sectionName=\"ALERT: US Boxed Warning\" href=\"#F5709009\" class=\"outlineLink\">ALERT: US Boxed Warning</a></li><li class=\"plainItem\"><a sectionName=\"Brand Names: US\" href=\"#F2407571\" class=\"outlineLink\">Brand Names: US</a></li><li class=\"plainItem\"><a sectionName=\"Brand Names: Canada\" href=\"#F6027963\" class=\"outlineLink\">Brand Names: Canada</a></li><li class=\"plainItem\"><a sectionName=\"Pharmacologic Category\" href=\"#F2407576\" class=\"outlineLink\">Pharmacologic Category</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Adult\" href=\"#F2407611\" class=\"outlineLink\">Dosing: Adult</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Geriatric\" href=\"#F2407612\" class=\"outlineLink\">Dosing: Geriatric</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Renal Impairment\" href=\"#F2407613\" class=\"outlineLink\">Dosing: Renal Impairment</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Hepatic Impairment\" href=\"#F16160282\" class=\"outlineLink\">Dosing: Hepatic Impairment</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Adjustment for Toxicity\" href=\"#F2407614\" class=\"outlineLink\">Dosing: Adjustment for Toxicity</a></li><li class=\"plainItem\"><a sectionName=\"Dosage Forms\" href=\"#F2407623\" class=\"outlineLink\">Dosage Forms</a></li><li class=\"plainItem\"><a sectionName=\"Generic Equivalent Available (US)\" href=\"#F2407574\" class=\"outlineLink\">Generic Equivalent Available (US)</a></li><li class=\"plainItem\"><a sectionName=\"Prescribing and Access Restrictions\" href=\"#F11234038\" class=\"outlineLink\">Prescribing and Access Restrictions</a></li><li class=\"plainItem\"><a sectionName=\"Medication Guide and/or Vaccine Information Statement (VIS)\" href=\"#F7874837\" class=\"outlineLink\">Medication Guide and/or Vaccine Information Statement (VIS)</a></li><li class=\"plainItem\"><a sectionName=\"Administration\" href=\"#F2407615\" class=\"outlineLink\">Administration</a></li><li class=\"plainItem\"><a sectionName=\"Hazardous Drugs Handling Considerations\" href=\"#F49104526\" class=\"outlineLink\">Hazardous Drugs Handling Considerations</a></li><li class=\"plainItem\"><a sectionName=\"Use\" href=\"#F2407578\" class=\"outlineLink\">Use</a></li><li class=\"plainItem\"><a sectionName=\"Use: Off-Label\" href=\"#F25473682\" class=\"outlineLink\">Use: Off-Label</a></li><li class=\"plainItem\"><a sectionName=\"Medication Safety Issues\" href=\"#F3401642\" class=\"outlineLink\">Medication Safety Issues</a></li><li class=\"plainItem\"><a sectionName=\"Adverse Reactions\" href=\"#F2407590\" class=\"outlineLink\">Adverse Reactions</a></li><li class=\"plainItem\"><a sectionName=\"Contraindications\" href=\"#F2407586\" class=\"outlineLink\">Contraindications</a></li><li class=\"plainItem\"><a sectionName=\"Warnings/Precautions\" href=\"#F2407587\" class=\"outlineLink\">Warnings/Precautions</a></li><li class=\"plainItem\"><a sectionName=\"Metabolism/Transport Effects\" href=\"#F13299581\" class=\"outlineLink\">Metabolism/Transport Effects</a></li><li class=\"plainItem\"><a sectionName=\"Drug Interactions\" href=\"#F2407598\" class=\"outlineLink\">Drug Interactions</a></li><li class=\"plainItem\"><a sectionName=\"Pregnancy Implications\" href=\"#F2407581\" class=\"outlineLink\">Pregnancy Implications</a></li><li class=\"plainItem\"><a sectionName=\"Breast-Feeding Considerations\" href=\"#F2407585\" class=\"outlineLink\">Breast-Feeding Considerations</a></li><li class=\"plainItem\"><a sectionName=\"Monitoring Parameters\" href=\"#F2407617\" class=\"outlineLink\">Monitoring Parameters</a></li><li class=\"plainItem\"><a sectionName=\"Mechanism of Action\" href=\"#F2407602\" class=\"outlineLink\">Mechanism of Action</a></li><li class=\"plainItem\"><a sectionName=\"Pharmacodynamics/Kinetics\" href=\"#F2407604\" class=\"outlineLink\">Pharmacodynamics/Kinetics</a></li><li class=\"plainItem\"><a sectionName=\"Pricing: US\" href=\"#F16322927\" class=\"outlineLink\">Pricing: US</a></li><li class=\"plainItem\"><a sectionName=\"Brand Names: International\" href=\"#F5539966\" class=\"outlineLink\">Brand Names: International</a></li><li class=\"plainItem\"><a href=\"#references\">REFERENCES</a></li></ul></div><div><h2>GRAPHICS <a href=\"#\" id=\"viewAllGraphicsLink\">View All</a></h2><div id=\"outlineGraphics\"><ul><li><div id=\"DRUG_GEN/9822|TAB\" class=\"openRelatedGraphics\"><a href=\"#\" title=\"TABLES\">TABLES</a></div><ul><li><a href=\"image.htm?imageKey=DRUG/57469\" class=\"graphic graphic_table\">- Lexicomp clinical abbreviations</a></li></ul></li></ul></div></div><div><h2>RELATED TOPICS</h2><div id=\"outlineTopics\"><ul><li><a href=\"topic.htm?path=lenalidomide-patient-drug-information\" class=\"drug drug_patient\">Lenalidomide: Patient drug information</a></li></ul></div></div>","javascript":null}